UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): August 19, 2009
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
_____________________
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE.
|
On August 18, 2009, Oramed Pharmaceuticals Inc. issued a press release announcing
that its Chief Scientific Officer, Miriam Kidron, Ph.D. was chosen to lecture at
the 2009 British Pharmaceutical Conference in Manchester, England on September
9, 2009.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated by reference herein.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
(d)
|
Exhibits
|
|
Exhibit
Number
|
Description
|
||
|
99.1
|
Press
Release dated August 18, 2009
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS
INC.
|
|||
|
Dated:
August 19, 2009
|
By:
|
/s/
Nadav Kidron
|
|
|
Nadav
Kidron
|
|||
|
President,
CEO and Director
|
|||
Exhibit
Index
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated August 18,
2009
|
Oramed’s
Chief Scientific Officer, Miriam Kidron, Ph.D., chosen to lecture at the 2009
British Pharmaceutical Conference in Manchester, England
JERUSALEM,
Israel – August 18, 2009– Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB)
(http://www.oramed.com), a developer of alternative drug delivery systems,
announced today that Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D. was
chosen to present an overview of the clinical development of Oramed's Oral
Insulin capsule at science@BPC
of the 2009 British Pharmaceutical Conference (“BPC”), in Manchester,
England on September 9, 2009.
Science@BPC is an event that
is the result of the collaboration between two organizations, the Royal
Pharmaceutical Society of Great Britain and the Academy of Pharmaceutical
Sciences. The two organizations describe the event as "the UK's premier
medicines discovery and development event, showcasing excellence in the
pharmaceutical sciences." The focus of the BPS
this year is the innovative discovery, delivery, and diagnostic technologies
aimed at fighting cancer, infectious diseases and diabetes.
Dr.
Kidron will present her lecture titled: "Oral Insulin: From Bench to Humans"
during the session titled: "Delivering Anti-diabetic Medicines." The
lecture will begin at 2:15 pm GMT (9:15 am EST, 6:15 am PST) on September 9,
2009. Dr. Kidron commented “Oramed is pleased to have been invited to the BPC to
share the clinical development of its Oral Insulin Capsule with the
pharmaceutical community."
About
Oramed Pharmaceuticals
Oramed
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed’s technology is based on over 25 years of
research by top research scientists at Jerusalem’s Hadassah Medical Center. The
Company’s corporate and R&D headquarters are based in
Jerusalem.
For more
information, please visit www.oramed.com.
Forward-looking
statements
Some of the statements contained in
this press release are forward-looking statements which involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and the company’s ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to the company’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors that
could cause actual results, performance or achievements of the company to differ
materially from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any forward-looking
statements.
Company
and Investor Relations Contacts:
Oramed
Pharmaceuticals
Tara
Horn
USA: +1
646-240-4193
Int’l: +
972-54-334-318
Office: +
972-2-566-0001
Email: tara@oramed.com